Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 70518-4362

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 70518-4362). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description for Rizatriptan Benzoate orally disintegrating tablets in 10 mg dosage with a quantity of 9 tablets. The tablets come in round white F25 form and are intended for prescription use only. The medication is repackaged by RemedyRepack Inc., located in Indiana, PA. Important warnings include not removing the tablet from blister packaging until consumption and a caution for phenylketonurics as the tablets contain phenylalanine. The manufacturer is Aurobindo from Magar, India. The medication should be stored at a temperature range of 15-30°C (59-86°F) and away from the reach of children. Additional dosage instructions can be found in the insert provided.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
This text discusses the estimated probability of achieving an initial headache response within 2 hours based on pooled data from four placebo-controlled outpatient trials. The Kaplan-Meier plot displayed in Figure 1 illustrates the probability over time of obtaining a headache response (no or mild pain) after treatment with rizatriptan benzoate or placebo. It also mentions that patients who did not achieve a headache response before 2 hours or received additional treatment were censored at 2 hours in the analysis. The study provides evidence of efficacy for the treatment based on the pooled data from the mentioned studies.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
The text provides an overview of the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 1, 2, 3, and 4. The Kaplan-Meier plot is based on data obtained from 4 placebo-controlled outpatient clinical trials. Patients not using additional treatments were censored at 24 hours. Remedication was not allowed within 2 hours post-dose.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)
This is an evaluation of the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 5 and 6. The data includes a Kaplan-Meier plot based on placebo-controlled outpatient clinical trials with patients who either responded or did not respond to the initial dose. The plot shows the percentage of patients taking additional treatments over time post-dose, with patients not using additional treatments being censored at 24 hours.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
This is a chart showing the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7 for Rizatriptan Benzoate OD Tablets compared to a Placebo. The x-axis represents hours post-stage 2 dose and the y-axis represents the percentage of patients with no headache pain. The chart demonstrates the effectiveness of Rizatriptan Benzoate OD Tablets in relieving headache pain based on the percentage of patients at 2 hours post-dose.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.